Prestige Biopharma and Pharmapark Sign an Exclusive License and Supply Agreement to Commercialize HD204 (biosimilar, bevacizumab) in Russia

 Prestige Biopharma and Pharmapark Sign an Exclusive License and Supply Agreement to Commercialize HD204 (biosimilar, bevacizumab) in Russia

Prestige Biopharma and Pharmapark Sign an Exclusive License and Supply Agreement to Commercialize HD204 (biosimilar, bevacizumab) in Russia

Shots:

  • Pharmapark to get exclusive rights to commercialize HD204 and is responsible for local registration, sales, and marketing of the biosimilar in Russia in collaboration with Russian import substitution strategy
  • Prestige BioPharma will be responsible for commercial supply the product out of its manufacturing facilities in Osong, Korea
  • Prestige’s (HD204) is currently being evaluated in P-III SAMSON-II trial that involves assessing the safety & efficacy of HD204 to the reference, Roche’s Avastin for multiple cancer indications

Click here to­ read full press release/ article | Ref: Business Wire | Image: CPhl Online

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post